10.8 C
Thursday, March 23, 2023

BeiGene (NASDAQ: BGNE) Announces the Opening of a New Regional Office in Basel

BeiGene, Ltd. (NASDAQ: BGNE) confirmed that it has opened a new regional office in Basel, Switzerland. BeiGene will strengthen its European presence with the opening of the Regional Office.  The launch in Basel builds on the organization’s expansion in Europe and will serve as a new hub for its operations in the region.

BeiGene, which was established in 2010, today has a global team of over 8,000 employees spread across five continents. BeiGene’s European organization currently employs over 270 people, with 150 people scheduled to work in the Basel office at first. Clinical trials are conducted by the company around the world, and patients have been enrolled from more than 45 countries, including 25 in Europe.

BeiGene has established a European organization, which includes commercial and clinical teams, and this new site will function as a regional hub for the company. Furthermore, BeiGene hosted numerous government representatives and corporate executives from the region for the opening ceremony, where they discussed the importance of biotechnology leaders like BeiGene to the wider Basel area.

BeiGene revealed that it has brought together a fantastic team, and Basel’s professional personnel network will help the company expand in the future. This is just the beginning as the company is on a quest to bring new medicines to more patients in Europe and around the world.

BeiGene’s presence also marks a great opportunity for the Swiss economy to grow and cooperate, said Deborah Strub, Member of the Executive Board and Head of the Basel Chamber of Commerce’s Cluster & Initiatives Department. The region’s economic engine is the life sciences sector. We see prospects for exciting synergies and exchanges with BeiGene.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.